X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
MGCD516 (sitravatinib) is an investigational spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
Lead Product(s): Sitravatinib,Nivolumab
Therapeutic Area: Oncology Product Name: MGCD516
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
MGCD516 (sitravatinib) is an investigational spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
Lead Product(s): Sitravatinib,Nivolumab
Therapeutic Area: Oncology Product Name: MGCD516
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
BeiGene is pursuing diverse mechanisms of action in combination with tislelizumab to complement targeting of the PD-1 pathway for potentially improved clinical outcomes or to overcome resistance associated with disease progression.
Lead Product(s): Tislelizumab,Sitravatinib
Therapeutic Area: Oncology Product Name: BGB-A317
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mirati Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2021
Details:
The combination of sitravatinib with nivolumab demonstrated promising clinical activity in checkpoint inhibitor-naïve, platinum-refractory patients.
Lead Product(s): Sitravatinib,Nivolumab
Therapeutic Area: Oncology Product Name: MGCD516
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2020
Details:
Joseph A. Leveque will assist Mirati to further advance its registration-enabling clinical trials for both sitravatinib and MRTX849, as well as advance its preclinical pipeline including the KRAS G12D inhibitor program.
Lead Product(s): Sitravatinib,Nivolumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2020
Details:
Mirati Therapeutics is conducting ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in combination with nivolumab in patients.
Lead Product(s): Sitravatinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
